Tumour markers in breast cancer.
The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, alpha subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81% of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide sensitive guide to tumour burden. CEA, lactalbumin and alpha subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.
D001943:Breast Neoplasms / Q000032:analysis / Q000175:diagnosis*; D002116:Calcitonin / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000032:analysis; D003600:Cytosol / Q000032:analysis; D005260:Female; D006242:Haptoglobins / Q000032:analysis; D006801:Humans; D007768:Lactalbumin / Q000032:analysis; D011257:Pregnancy Proteins / Q000032:analysis; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D013972:Thyrotropin / Q000032:analysis
D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D006242:Haptoglobins; D011257:Pregnancy Proteins; D013972:Thyrotropin; D002116:Calcitonin; D007768:Lactalbumin; D011266:Pregnancy-Associated Plasma Protein-A